Cover Story

Glucocorticoids (GCs) are extensively prescribed medicines due to their potent immuno­suppressive and anti-inflammatory properties. Prolonged high-dose GC use is associated with a range of metabolic side effects, including hyperphagia, obesity, and abnormal glucose homeostasis. The mechanisms driving these adverse metabolic effects remain unclear. A potential region involved in driving these GC-induced side effects is the hypothalamic arcuate nucleus, a region that is critical for the regulation of feeding and metabolism.

Wray et al. used a global transcriptomic approach to investigate the effects of GCs in the hypothalamus. This revealed a variety of genes involved in energy regulation, of which type-II iodothyronine deiodinase (Dio2) was selected as the most promising candidate for further study. A knockdown of Dio2 attenuated the GC-induced increase in Agrp; however, knockdown conferred no protection from the observed hyperphagia or weight gain. The range of both known and novel candidate genes indicates that multiple mechanisms may contribute to the metabolic abnormalities observed with GC treatment.

The 60 Second Metabolist
In this section authors briefly report on their work recently published in Molecular Metabolism.

Watch the most recent interview by clicking the video still. The link "referring article" directs you to this author's publication.

Daniela Cota
INSERM, Bordeaux, France
Referring article

Other Scientists...
Issue Alert
If you want to be alerted via email when new content that matches your interests is available, please login or register at
Conferences & Events
15 − 18
Nature Conference: Advances in Metabolic Communication
Rio de Janeiro, Brasil
15 − 18
13th European Nutrition Conference
Dublin, Ireland
27 − 31
Metabolism in Action
Hillerod, Denmark
6 − 8
Cachexia, Sarcopenia and Muscle Wasting
Berlin, Germany
Media Coverage
Supported by